Groups | A(N) | B(N) | C(N) | D(N) | E(N) | ||
Inoculation route | I.N. | I.M. | |||||
PRV strain tested | PRVΔTK&gE-AH02 | LA-AB | PRVΔTK&gE-AH02 | LA-AB | |||
ELISA antibodies against PRV gB or gE | B.I. | gB+ | 0a/4b | 0/4 | 0/4 | 0/4 | 0/4 |
14d P.I. | gB+ | 3/3 | / | 4/4 | 1/1 | 0/4 | |
gE+ | 0/3 | / | 0/4 | 0/1 | 0/4 | ||
Morbidity | 2/4 | 4/4 | 1/4 | 4/4 | 0/4 | ||
Mortality | 1/4 | 4/4 | 0/4 | 3/4 | 0/4 | ||
Groups | A(P) | B(P) | C(P) | D(P) | E(P) | ||
Inoculation route | I.N. | I.M. | |||||
PRV strain tested | PRVΔTK&gE-AH02 | LA-AB | PRVΔTK&gE-AH02 | LA-AB | |||
ELISA antibodies against PRV gB or gE | B.I. | gB+ | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 |
14d P.I. | gB+ | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | |
gE+ | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | ||
Morbidity | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | ||
Mortality | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |